Coherus BioSciences (CHRS) Announces Results of Study Demonstrating CHS-0214 Equivalence to Enbrel
Tweet Send to a Friend
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced the release of study data demonstrating the equivalence of Coherus’ etanercept biosimilar (CHS-0214) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
